Multiple System Atrophy (MSA) Clinical Trial
Official title:
Multiple System Atrophy Multidisciplinary Clinic
NCT number | NCT03811808 |
Other study ID # | STU 082015-008 |
Secondary ID | |
Status | Recruiting |
Phase | |
First received | |
Last updated | |
Start date | March 2016 |
Est. completion date | March 2028 |
This is a prospective cohort study to examine the disease burden of multiple system atrophy and the impact of multidisciplinary care on quality of life and caregiver burden. Data will be collected through valid rating scales completed by patients and caregivers at home or in the MSA clinic.
Status | Recruiting |
Enrollment | 200 |
Est. completion date | March 2028 |
Est. primary completion date | March 2028 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Subject must be a patient in the UT Southwestern MSA clinic and be able to attend the multidisciplinary clinic every 4 months - Patients with possible or probable MSA based on established criteria - Subjects must be 18 years or older Exclusion Criteria: - Patients that are unable to give consent - Minor patients (younger than age 18) - Non-English speaking patients - Subjects that are diagnosed with dementia |
Country | Name | City | State |
---|---|---|---|
United States | UT Southwestern Medical Center | Dallas | Texas |
Lead Sponsor | Collaborator |
---|---|
University of Texas Southwestern Medical Center |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Composite Autonomic Symptom Score (CONPASS 31) | Compass 31 scale includes 31 questions and it will be used to assess autonomic symptoms that provides clinically relevant scores of autonomic symptom severity based. The higher the score the more autonomic symptoms present | at 5 year evaluation | |
Other | Center for Epidemiologic Studies Depression Scale (CES-D) | The CES-D measures symptoms defined by the American Psychiatric Association' Diagnostic and Statistical Manual (DSM-V) for a major depressive episode. The higher the scores and indicative for depression present. | at 5 year evaluation | |
Other | The Orthostatic Hypotension Questionnaire (OHQ) | The OHQ is used to assess the comprehensive symptom burden and severity of neurogenic orthostatic hypotension (NOH). | at 5 year evaluation | |
Primary | Multiple System Atrophy-Quality of Life (MSA-QoL) | The disease burden of MSA and impact of multidisciplinary care on the quality of life of patients as measured by the MSA-Quality of Life (QOL) questionnaire completed every four months by the patients. The scale measures how MSA affects a person's quality of life in day to day activities. The scale ranges from No problem to Extreme Problem. The More Extreme Problem sections selected the more their quality of life is affected by the disease. | at 5 year evaluation | |
Secondary | Unified Multiple System Atrophy Rating Scale (UMSARS) | The UMSARS completed every four months by the physician. The scale measures how MSA has progressed from baseline. The higher the score the higher the progression is. | at 5 year evaluation | |
Secondary | Caregiver Burden Index/ The Zarit Burden Interview | The disease burden of MSA and impact of multidisciplinary care on caregiver burden as measured by the Burden Index of Caregivers (BIC) questionnaire and The Zarit Burden Interview completed every four months by the caregivers. The higher the higher the score the more burden the caregiver has. | at 5 year evaluation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05923866 -
A Phase 2 Study of ONO-2808 in Patients With Multiple System Atrophy
|
Phase 2 | |
Recruiting |
NCT02778607 -
PROgressive Supranuclear Palsy CorTico-Basal Syndrome Multiple System Atrophy Longitudinal Study UK
|
||
Completed |
NCT01485549 -
Oligomeric Alpha-synuclein in Multiple System Atrophy
|
||
Completed |
NCT02796209 -
Norepinephrine Transporter Blockade, Autonomic Failure
|
Phase 2 | |
Completed |
NCT04193527 -
A Study to Evaluate the Diagnostic Efficacy of DaTSCAN™ Ioflupane (123I) Injection in Single Photon Emission Computed Tomography (SPECT) for the Diagnosis of Parkinsonian Syndrome (PS) in Chinese Patients
|
Phase 3 | |
Completed |
NCT01888185 -
Identifying Biomarkers of Parkinson's Disease Using Magnetic Resonance Imaging (MRI)
|
||
No longer available |
NCT05086094 -
Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)
|